Vevorisertib trihydrochloride

Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan- AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT . Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC 50 values of 0.55, 0.81, and 1.3 nM for AKT1 , AKT2 , and AKT3 , respectively. Vevorisertib trihydrochloride can be used for the research of cancer In Vitro Vevorisertib trihydrochloride (0, 12, 33, 111, 333, 1000 nM, 2 hours) inhibits phosphorylation of AKT1-E17K. Vevorisertib trihydrochloride (1 μM for 2 hours; NIH 3T3 cells are transfected with either pcDNAAKT-WT-GFP or pcDNA-E17K-GFP) inhibits plasma membrane translocation of AKT-WT and AKT1-E17K irrespective of the presence of growth factors. Vevorisertib trihydrochloride (5 μM) exhibites 57% inhibition of full-length AKT1. Vevorisertib trihydrochloride (0, 0.012, 0.037, 0.11, 0.33, 1 μM; 2 hours) shows a dose-dependent effect on mTORC1 and AKT direct substrates including PRAS40, GSK3β, FOXO, BAD, and AS160 in cancer cell lines. Vevorisertib trihydrochloride has anti-proliferative effect on esophageal, breast, and head and neck cancer cells (GI 50 In Vivo Vevorisertib trihydrochloride (25, 50 and 75 mg/kg; p.o.; 5 days dosing followed by a 4 day dosing holiday for 20 days) shows potent tumor growth inhibition of 68, 78 and 98%, respectively . Vevorisertib trihydrochloride (5, 10, 20, 40, 80, and 120 mg/kg; p.o. daily for ten days) shows tumor growth inhibition of 29, 33, 50, 73, 83, and 92%, respectively . Vevorisertib trihydrochloride reachs C max plasma concentrations of ≥2 μM . Vevorisertib trihydrochloride is generally well-tolerated at dose levels up to 120 mg/kg . Vevorisertib trihydrochloride (MK-4440)/IM combination shows superior efficacy in an IM-sensitive preclinical model of GIST compared with either single agent. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Endometrial PDX mouse xenograft models (AKT1-E17K mutation tumor fragments subcutaneously implanted in athymic nude mice; tumor volume of approximately 200 mm 3 ) Dosage: 25, 50 and 75 mg/kg Administration: p.o.; 5 days dosing followed by a 4 day dosing holiday for 20 days Result: Showed potent tumor growth inhibition of 68, 78 and 98%, respectively. Animal Model: AN3CA mouse xenograft models (female NCr nu/nu mice with 250 mm 3 tumors size) Dosage: 5, 10, 20, 40, 80, and 120 mg/kg Administration: p.o.; daily for ten days Result: Showed tumor growth inhibition of 29, 33, 50, 73, 83, and 92%, respectively. Form:Solid IC50& Target:Akt1 0.55 nM (IC 50 ) Akt2 0.81 nM (IC 50 ) Akt3 1.31 nM (IC 50 ) Akt1 1.2 nM (Kd) Akt1 E17K 8.6 nM (Kd)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet